Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nicolaas Bohnen, MD, PhD

Criteria

Inclusion Criteria:

• Healthy control volunteers over 45 years of age

• People with Parkinson Disease over 45 years of age

Exclusion Criteria:

• Subjects with contra-indications to MR imaging, including pacemakers or claustrophobia;

• Evidence of large vessel stroke or mass lesion on MRI

• Regular use of anti-cholinergic, benzodiazepines or neuroleptic drugs

• History of significant GI disease

• Significant metabolic or uncontrolled medical comorbidity

• Poorly controlled diabetes

• Pregnancy or breast feeding

• Dementia requiring informed assent

• Suicidal ideation